Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – Time to Sell?

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.40 and traded as high as $4.40. Achieve Life Sciences shares last traded at $4.38, with a volume of 467,452 shares trading hands.

Analyst Ratings Changes

ACHV has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Weiss Ratings raised Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the company a “buy” rating in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $14.67.

Achieve Life Sciences Trading Down 0.2%

The firm has a 50 day simple moving average of $3.92 and a 200 day simple moving average of $4.41. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $233.15 million, a PE ratio of -3.37 and a beta of 2.25.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Equities analysts expect that Achieve Life Sciences, Inc. will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Achieve Life Sciences

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new stake in Achieve Life Sciences during the 1st quarter valued at $32,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences during the 4th quarter valued at $64,000. Next Capital Management LLC purchased a new stake in Achieve Life Sciences during the 3rd quarter valued at $51,000. Jefferies Financial Group Inc. purchased a new stake in Achieve Life Sciences during the 4th quarter valued at $84,000. Finally, HRT Financial LP purchased a new stake in Achieve Life Sciences during the 4th quarter valued at $93,000. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.